Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Web Exclusives
Web Exclusive Articles
Webinars
Search ...
Hematologic Cancers
Imatinib Can Be Safely Discontinued in Patients with Deep Molecular Response
By
Chase Doyle
Hematologic Cancers
Web Exclusives
Long-term follow-up of the French 1 Stop Imatinib Study (STIM1) in patients with chronic myeloid leukemia (CML) has demonstrated that imatinib (Gleevec) can be safely discontinued in patients with a deep molecular response (ie, lasting at least 2 years). According to data presented at ASH 2015, molecular relapse was very rare after 6 months of stopping imatinib, and no relapse was reported after 2 years.
Read More
Self-Reports of 6-Mercaptopurine Intake in Childhood Acute Lymphoblastic Leukemia Unreliable
By
Phoebe Starr
Hematologic Cancers
Web Exclusives
Approximately 40% of children with acute lymphoblastic leukemia (ALL) fail to take 6-mercaptopurine (6-MP) as prescribed, and a sizable majority of parents and children with ALL overreport the intake of a critical drug for maintaining remission, according to a study reported by lead investigator Wendy Landier, PhD, RN, NP, Children’s of Alabama, Birmingham, and colleagues at ASH 2015. The study suggests that electronic reporting using TrackCap, a medication event monitoring system (MEMS), is more reliable than self-reports.
Read More
Search ...
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Web Exclusives
Web Exclusive Articles
Webinars
Subscribe to
Value-Based Care in Neurology
Stay up to date with personalized medicine by subscribing to receive the free
VBCN
e‑Newsletter.
I'd like to receive:
VBCN
e‑Newsletter
I have reviewed and consent to the terms of
VBCN
's
Privacy Policy
, and
VBCN
has my permission to retain my information in its database, and to forward pertinent communications to me.